Seto

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease2 trials
• Stroke2 trials
• Childhood cancers1 trial
• Chronic myeloid leukaemia1 trial

Phase

• Phase 32 trials

Status

• Completed2 trials
• Active, not recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals3 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

Closed trials

• Completed

  Special Drug Use-results Surveillance of Scemblix Tablets

  NCT05421091· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source